Amgen (NASDAQ:AMGN) Rating Increased to Sell at BidaskClub
Amgen (NASDAQ:AMGN) was upgraded by research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Friday, BidAskClub reports.
Several other research analysts have also recently weighed in on the company. Truist upgraded Amgen from a “hold” rating to a “buy” rating in a research report on Monday, October 12th. SVB Leerink increased their price objective on Amgen from $243.00 to $253.00 and gave the stock a “market perform” rating in a research report on Wednesday, December 9th. UBS Group started coverage on Amgen in a research report on Wednesday, October 28th. They set a “neutral” rating and a $232.00 price objective on the stock. Bank of America lowered their price objective on Amgen from $275.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. Finally, William Blair reissued a “hold” rating on shares of Amgen in a report on Wednesday, September 23rd. Three research analysts have rated the stock with a sell rating, twelve have given a hold rating and eighteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $254.92.
AMGN opened at $229.92 on Friday. Amgen has a 1-year low of $177.05 and a 1-year high of $264.97. The stock’s fifty day simple moving average is $227.37 and its 200 day simple moving average is $238.32. The company has a current ratio of 2.28, a quick ratio of 1.88 and a debt-to-equity ratio of 3.12. The stock has a market cap of $133.85 billion, a PE ratio of 18.54, a price-to-earnings-growth ratio of 1.83 and a beta of 0.76.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Monday, November 2nd. The medical research company reported $4.37 earnings per share for the quarter, topping the consensus estimate of $3.75 by $0.62. The firm had revenue of $6.42 billion for the quarter, compared to analysts’ expectations of $6.38 billion. Amgen had a return on equity of 95.55% and a net margin of 29.42%. Equities analysts forecast that Amgen will post 16.15 earnings per share for the current year.
In other news, Director R Sanders Williams sold 250 shares of Amgen stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $242.40, for a total transaction of $60,600.00. Following the sale, the director now directly owns 4,909 shares of the company’s stock, valued at $1,189,941.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.36% of the company’s stock.
Several hedge funds have recently made changes to their positions in AMGN. Advisory Alpha LLC acquired a new stake in shares of Amgen during the third quarter valued at about $25,000. JFG Wealth Management LLC acquired a new stake in shares of Amgen during the third quarter valued at about $28,000. Baron Financial Group LLC acquired a new stake in shares of Amgen during the third quarter valued at about $51,000. Paces Ferry Wealth Advisors LLC bought a new position in shares of Amgen during the third quarter worth about $52,000. Finally, Demars Financial Group LLC bought a new position in shares of Amgen during the second quarter worth about $53,000. 71.72% of the stock is currently owned by hedge funds and other institutional investors.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease.
Further Reading: Retained Earnings
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Transportation Stocks You Can’t Ignore
There is a situation developing in the U.S. that will drive revenue and profits for the transportation industry for many years to come. It started to develop with the pandemic, began to grow when the recession was less than expected, and was later compounded by an economic rebound that is much stronger than expected.
When the pandemic struck and lock-downs took effect manufacturers shuttered their plants and supply chains dried up. When Congress sent out the stimulus checks it sparked a round of consumer spending that has wiped products off of shelves. Now, with inventories across industries reportedly down high-single to low-double digits from the previous year, there is a need for 1) manufacturing to meet demand and rebuild inventory and 2) transportation/shipping that is growing by the day.
We have compiled a list of 7 transportation stocks that can’t be ignored,
Published at Fri, 01 Jan 2021 08:14:56 +0000